Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2000, p. 3755-3758, Vol. 38, No. 10
Department of Biology, Northeastern
University,1 Division of
Gastroenterology, St. Elizabeth's Medical
Center,2 and Division of
Gastroenterology, New England Medical Center,3
Boston, Massachusetts
Received 11 February 2000/Returned for modification 18 April
2000/Accepted 18 July 2000
In order to improve detection and identification of
Helicobacter pylori in highly contaminated samples, we
evaluated new specific primers based on the DNA base sequence within
the isocitrate dehydrogenase (icd) gene to amplify a
1,200-bp DNA segment. The specificity of the icd primer was
tested against DNA derived from various bacteria, including 7 Helicobacter species and a panel of 1 gram-variable, 2 gram-positive, and 16 gram-negative bacteria, as well as DNA from
houseflies and feces from H. pylori-negative patients. The primers permitted the detection of all clinical H. pylori
isolates tested, but no reactions were observed with negative controls. Several procedures for DNA extraction from feces were evaluated using
PCR with icd primers. The lower limits of detection of
H. pylori DNA from two different sources containing the
same number of H. pylori organisms, a pure culture and
feces spiked with H. pylori, were established for each
extraction method tested. The results were 8.0 × 103
CFU/ml for cultures of pure H. pylori, and 8.0 × 106 CFU/ml for H. pylori from feces, using the
phenol-chloroform method; 8.0 × 102 and 7.0 × 103 CFU/ml, respectively, for a glass matrix and chaotropic
solution protocol; 8.0 × 102 and 7.0 × 103 CFU/ml, respectively, for the QIAamp tissue kit; and
5.0 × 102 and 5.0 × 103 CFU/ml,
respectively, for the XTRAX DNA extraction kit. We conclude that the
use of the icd gene as a primer for PCR represents a specific and sensitive assay for detection of H. pylori in
highly contaminated samples.
Helicobacter pylori is
strongly associated with gastroduodenal disease, including chronic
active gastritis, duodenal ulcers, and gastric adenocarcinoma
(1). Several reliable methods for detecting H. pylori are used at present; most of them are performed on gastric
biopsy samples. Since these methods are thus invasive and expensive,
less-invasive methods such as serologic examination of blood and the
urea breath test are becoming more popular (27). However,
these noninvasive tests have drawbacks: positive results by blood
serology do not necessarily indicate current infection by H. pylori (D. J. Cullen, K. J. Cullen, B. J. Collins,
K. J. Christiansen, and J. Epis, Letter, Lancet
340:1161-1162, 1992), while urea breath tests require
expensive, specialized equipment and reagents (2).
Considering these drawbacks of such noninvasive tests, alternative
methods with feces appear attractive.
In a limited number of studies, infected individuals have been shown to
excrete H. pylori in feces, since PCR, enzyme immunoassay (EIA), or even culture could detect the organisms in stool specimens (7-9, 20, 23). However, many others have not yet confirmed these findings. In fact, culture of H. pylori is
extraordinarily problematic due to the complexity of the fecal
microflora, making direct culture of H. pylori difficult and
subject to misinterpretation. Further limiting factors of isolation are
technical, such as the requirement for a selective medium to culture
H. pylori reliably from fecal samples. Hence, PCR has been
used to detect H. pylori DNA; however, it has been shown to
have its own limitations. For example, extraction of PCR-amplifiable
DNA from feces has been a complicated and lengthy process
(20). A variety of inhibitors present in feces can lead to
erratic results (12, 24). In addition, the correct choice of
highly specific and sensitive primers and the correct conformation of
the amplified product are clearly essential for optimal sensitivity and
specificity (10). We have recently isolated and expressed
the isocitrate dehydrogenase gene (icd) of H. pylori (6). The DNA sequence of the icd gene
was 96% identical to that present in the total-genome sequence of
H. pylori strain 26695 (21) and only 64%
homologous to the icd of Escherichia coli, 64%
homologous to Vibrio sp. icd, and 63% homologous
to Bacillus subtilis icd. Furthermore, the 3' sequence was
unique based on gene bank analysis. The aim of our study was to
evaluate several procedures for extracting H. pylori DNA
from feces and to evaluate newly designed primers based on the DNA
sequence within the icd gene for PCR. An effective combination of DNA extraction and amplification may improve detection of H. pylori in the environment and in clinical settings.
Controls for primer specificity.
Bacterial strains, flies,
and fecal samples used as controls are listed in Table
1.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Evaluation of a PCR Primer Based on the Isocitrate
Dehydrogenase Gene for Detection of Helicobacter pylori
in Feces
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Specificity of icd primers in detecting
H. pylori DNA
80°C in 20% (vol/vol) glycerol-Brucella broth.
Seven different Helicobacter species were cultured like the
clinical isolates above in order to assess the specificity of our
icd primers. Furthermore, we tested the icd
primers against houseflies (Musca domestica) and human
feces. Fecal samples were obtained from patients proven H. pylori negative by histology of endoscopically obtained gastric
biopsy specimens and were tested individually. In this study, feces
from H. pylori-positive patients was not used for the
evaluation of the sensitivity and specificity of our PCR methods, since
the number of H. pylori organisms in these samples is
unknown. The purpose of our work was to evaluate our primers and DNA
extraction methods; therefore, samples with defined H. pylori loads were used.
Flies were chosen as controls because they contain a large variety of
viral, bacterial, and parasite DNA, as well as food and host DNA
(5). In addition, we recently reported that flies are able
to carry and excrete viable H. pylori and may therefore represent a vector for the transmission of H. pylori
(4). Several hundred housefly pupae (Carolina Biological
Supply Company, Burlington, N.C.) were placed in well-ventilated
autoclaved buckets maintained at 25°C. Emerging adult flies were
removed, and pools of five flies were transferred into sterile test
containers and frozen at
80°C until subsequent preparation for PCR.
For DNA extraction, flies were thawed. The abdomen of each fly was
separated aseptically from the chest under a dissecting microscope. The
bodies of each fly pool were homogenized in 0.5 ml of sterile water by
using a sterile glass grinder. All bacterial and fecal samples, as well as fly homogenates, were processed by using the XTRAX kit (see below)
to purify genomic DNA for PCR.
PCR. PCR was used to identify the icd gene of H. pylori in our samples. Chromosomal DNA was prepared as described under "DNA extraction and method sensitivity" below. Oligonucleotide primers (Tufts University Protein and Nucleic Acid Analysis Unit, Boston, Mass.), were specific for the 5' and 3' termini of the icd gene respectively, with the sequences 5'-ATGGCTTACAACCCTAAAATTTTACAAAAGCC-3' and 5'-TCACATGTTTTCAATCATCACGC-3'. The reaction was performed in a volume of 100 µl, comprising 50 pM each primer, 10 µl of chromosomal DNA, 2 U of Taq DNA polymerase (Boehringer Mannheim Biochemicals), 0.2 mM deoxynucleoside triphosphates, and 1.5 mM MgCl2, in a single block thermal cycler (Ericomp, San Diego, Calif.). Cycle profiles were as follows: DNA denaturation at 94°C for 5 min, followed by 30 cycles consisting of 1-min denaturation at 94°C, 2-min annealing at 55°C, and 2-min extension at 72°C. Samples were run simultaneously with a clinical H. pylori isolate as a positive control. Negative-control reactions with distilled water were performed with each batch of amplification to exclude the possibility of contamination. The specificity of icd primers was compared with that of species-specific protein antigen primers, which have been reported to be highly specific for H. pylori (14). Species-specific protein antigen and icd primers were tested against control flies, H. pylori, and the non-Helicobacter control bacteria listed in Table 1. In addition, icd primers were studied with seven Helicobacter species. PCR products were analyzed by electrophoresis of a 10-µl aliquot using a 1.3% (wt/vol) agarose gel. Bands were visualized by excitation under UV light after staining with 1 µg of ethidium bromide/ml.
Target DNA sequence determination. DNA sequencing was performed on the amplified products in order to eliminate false-positive results. DNA was extracted from 90 µl of the reaction mixture by using a PCR purification kit (QIAGEN, Hilden, Germany). Double-stranded DNA PCR was carried out by the dideoxy chain termination method (15) with Taq DNA polymerase (GIBCO BRL) by using the same oligonucleotide primers specific for the icd gene as in the PCR.
DNA extraction and method sensitivity. In the present study, four methods to purify DNA from one pure clinical H. pylori isolate in suspension as well as from spiked fecal samples were compared, as follows.
(i) The classical phenol-chloroform method (11). Protein was denatured using STE buffer with 1% sodium dodecyl sulfate and 25 µg proteinase of K, and DNA was concentrated in the aqueous layer using phenol-chloroform. Ethanol was then used to remove residual phenol-chloroform and salts and to precipitate the DNA.
(ii) Glass matrix and chaotropic solution (18). Guanidine-thiocyanate was used to lyse cells and denature proteins. DNA was bound to glass beads (GlasPac; National Scientific Supply Company, San Rafael, Calif.), and the suspension was washed in wash buffer (50% ethanol, 10 mM Tris-HCl [pH 7.5], 100 mM NaCl).
(iii) QIAamp tissue kit (Qiagen). Proteins were denatured using proteinase K. DNA was bound to the silica membrane of spin columns, leading to the removal of other contaminants by washing with buffers provided in the QIAamp kit.
(iv) XTRAX DNA extraction kit (Gull Laboratories, Salt Lake City, Utah) (26). Samples were microwaved in the presence of an extraction buffer containing detergents and salts, followed by centrifugation and DNA precipitation with isopropyl alcohol.
DNA was extracted from an H. pylori dilution series (100 to 10
6, beginning with an optical
density at 600 nm [OD600] of 1.0), using 100 µl of a
pure H. pylori suspension in one series and 50 µl of the
creamy layer of a stool sample spiked with 100 µl of bacterial
suspension in the other. The creamy layer contains fecal bacteria in a
more concentrated form and was prepared as described by Thomas
(19). In brief, stool samples were centrifuged (7,000 × g for 10 min) to separate three identifiable layers: a
liquid supernatant on top, a creamy layer in the middle, and a solid
layer on the bottom.
Quantification of H. pylori present in bacterial suspensions
and in aliquots used to spike stool samples was performed by plate
counts on Skirrow's agar (Difco, San Jose, Calif.).
PCR using the icd primers was performed to determine the
sensitivities of the extraction methods (see the protocols above).
| |
RESULTS |
|---|
|
|
|---|
Our icd primers proved to be very specific for H. pylori only and did not result in false-positive results with any of the other bacterial species, including seven Helicobacter species (Table 1). In addition, these primers specifically amplified H. pylori DNA from feces and fly abdomens, which represent a pool of heterogeneous DNA. This underlines the usefulness of these primers in the detection of H. pylori in highly contaminated samples, such as flies and stool. In contrast, the species-specific antigen primers (14) produced false-positive signals in our initial screening tests and reacted with negative-control flies, Campylobacter jejuni, and E. faecalis (data not shown).
The DNA sequence of the amplified target DNA of our controls confirmed the PCR products with more than 96% homology to the icd gene. The control clinical isolates of H. pylori showed 95% to 97% homology to the icd gene of reference strain 26695 (21). The fact that the sequences are not identical minimizes the chance that contamination occurred during sample preparation.
In comparison with two other DNA extraction techniques, the QIAamp kit
and the XTRAX kit proved to be the preferred methods due to their
sensitivity and the fact that complete kits reduce the length and
number of preparatory steps (see Table
2). Extraction using
guanidine-thiocyanate, however, was as sensitive as the QIAamp and
XTRAX techniques for pure H. pylori as well as for bacteria
from feces but was less convenient, since it required more preparation.
Phenol-chloroform extraction recovered the smallest amount of DNA from
pure and fecal H. pylori, and exposes one to harmful fumes
(Table 2).
|
| |
DISCUSSION |
|---|
|
|
|---|
This study shows that the icd gene PCR assay is a sensitive and specific method for the detection of H. pylori in feces. Comparison of four DNA extraction protocols that included columns, centrifugation, glass matrices, or patented extraction matrices showed that the QIAamp method and XTRAX kit were the best procedures due to their sensitivity and convenience of execution.
Isolation of H. pylori from feces as a diagnostic tool or for research purposes for detecting colonization is attractive because it is noninvasive. However, culture of H. pylori from patients' fecal samples has been problematic because currently available selective culture media for isolation of H. pylori are frequently overgrown by other, faster-growing gram-negative bacteria. Similarly, detection of H. pylori in feces by using PCR and standard extraction methods has proved difficult, producing erratic results due to a variety of fecal inhibitors, such as acidic polysaccharides, metabolic products, and large amounts of irrelevant DNA (12). Furthermore, previous PCR analysis for H. pylori in feces has shown low sensitivity (24) due to by multiple factors such as variations in the sensitivity and amplification performance of the polymerase and in the annealing affinity of the chosen primers to their target sequence (17). For this reason, DNA extraction procedures that remove inhibitors of PCR and concentrate the pathogen or total DNA were developed. In concert with these effective techniques, our highly specific icd primer represents a specific and sensitive method for detection of H. pylori.
Makristathis et al. (8) described species-specific protein antigen primers as specific for H. pylori, using only one other Helicobacter species to assess specificity. Our screening experiments, which included all the bacterial species listed in Table 1, as well as flies, showed that the use of these primers resulted in false-positive amplifications with control flies, C. jejuni, and E. faecalis. It is therefore possible that Makristathis' assay may have amplified non-H. pylori DNA, resulting in false positives. We demonstrated that the icd primers were more specific for H. pylori than the species-specific protein antigen primers when tested against a variety of DNA samples. Others have used primers based on the 16S rRNA, which have also displayed good specificity when tested against many microorganisms, including several Helicobacter species (16, 25), although no studies have been performed to assess the detection limit of these primers for H. pylori in feces.
The minimum number of organisms in feces required for a positive PCR result was 3.3 × 104 CFU/ml of stool in our most sensitive assay, which is comparable to other reported sensitivities (24). Despite concentrating H. pylori organisms by immunomagnetic-bead separation techniques, Osaki et al. showed comparable detection limits of 2 × 104 CFU for fecal samples obtained from gnotobiotic mice (13). Similar numbers, 1.8 × 104 CFU, are required for the recently developed stool antigen test (HpSA-EIA) (3). The HpSA-EIA is another attractive, noninvasive fecal test that seems to predict H. pylori status reliably (23), but it has been less suitable for evaluating the outcome of eradication therapy (22).
Another variable that may limit routine clinical use of fecal assays is the fact that H. pylori proteins or DNA, to be tested, have to pass unharmed through the entire gastrointestinal tract despite exposure to numerous digestive enzymes and bacteria. Furthermore, it is unknown how many H. pylori organisms an infected individual excretes, whether there is patchy distribution in a bowel movement, and how long H. pylori fragments remain in the intestinal tract after eradication therapy. Two recent studies showed that there was still significant detection of H. pylori debris by PCR as well as EIA at a 1-month follow-up for patients from whom H. pylori had been eradicated (8, 22). Hence, more data on the intestinal elimination kinetics of H. pylori are necessary in order to use molecular or immunoassay tests for evaluation of eradication treatment.
In conclusion, the icd gene assay has been shown to allow differentiation of H. pylori from seven other Helicobacter species. This newly designed primer pair may be useful for PCR used in epidemiological studies (P. Grübel, L. Huang, N. Masubuchi, F. J. Stutzenberger, and D. R. Cave, Letter, Lancet 352:788-789, 1998). In a next step, we will test the icd primers on feces from H. pylori-positive patients to evaluate their potential for clinical application.
| |
ACKNOWLEDGMENTS |
|---|
The support given by C. Mepani, N. Stern, and F. J. Stutzenberger in providing the bacterial control specimen and by Z. Shen and J. G. Fox in providing the Helicobacter species is gratefully acknowledged.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: St. Elizabeth's Medical Center, Division of Gastroenterology, 736 Cambridge St., Boston, MA 02135. Phone: (617) 789-2423. Fax: (617) 789-2427. E-mail: apgrubel{at}massmed.org.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Anonymous. 1994. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272:65-69[CrossRef][Medline]. |
| 2. | Bazzoli, F., M. Zagari, S. Fossi, P. Pozzato, L. Ricciardiello, C. Mwangemi, A. Roda, and E. Roda. 1997. Urea breath tests for the detection of Helicobacter pylori infection. Helicobacter 2(Suppl. 1):S34-S37. |
| 3. | Grübel, P., R. W. Frenck, D. H. Willis, P. J. Goddard, R. R. Abu-Elyazeed, A. Naficy, and D. R. Cave. 1999. HpSA enzyme immunoassay for detection of H. pylori from stool samples collected from a field setting in Egypt. Gastroenterology 116:G0772. (Abstract.) |
| 4. | Grübel, P., J. S. Hoffman, F. K. Chong, N. A. Burstein, C. Mepani, and D. R. Cave. 1997. Vector potential of houseflies (Musca domestica) for Helicobacter pylori. J. Clin. Microbiol. 35:1300-1303[Abstract]. |
| 5. | Grübel, P., and D. R. Cave. 1998. Sanitation and houseflies (Musca domestica): factors for the transmission of Helicobacter pylori. Bull. Inst. Pasteur 96:83-91[CrossRef]. |
| 6. | Huang, L. L., D. R. Cave, and A. Wright. 1996. Sequencing and expression of the gene encoding a novel protein with gastric acid inhibitory properties from Helicobacter pylori. Gut 39:A66. (Abstract.) |
| 7. | Kelly, S. M., M. C. Pitcher, S. M. Farmery, and G. R. Gibson. 1994. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 107:1671-1674[Medline]. |
| 8. |
Makristathis, A.,
E. Pasching,
K. Schutze,
M. Wimmer,
M. L. Rotter, and A. M. Hirschl.
1998.
Detection of Helicobacter pylori in stool specimens by PCR and antigen enzyme immunoassay.
J. Clin. Microbiol.
36:2772-2774 |
| 9. | Mapstone, N. P. 1993. PCR identification of Helicobacter pylori in faeces from gastritis patients. Lancet 341:447[Medline]. |
| 10. | Mapstone, N. P. 1997. The detection of Helicobacter pylori by the polymerase chain reaction, p. 31-36. In C. L. Clayton, and H. L. T. Mobley (ed.), Helicobacter pylori protocols. Humana Press, Totowa, N.J. |
| 11. | Monteiro, L., C. Birac, and F. Megraud. 1996. Detection of Helicobacter pylori in gastric biopsies by polymerase chain reaction, p. 112-120. In A. Lee, and F. Megraud (ed.), Helicobacter pylori: techniques for clinical diagnosis and basic research. W. B. Saunders Ltd., London, England. |
| 12. | Monteiro, L., D. Bonnemaison, A. Vekris, K. G. Petry, J. Bonnet, R. Vidal, J. Cabrita, and F. Megraud. 1997. Complex polysaccharides as PCR inhibitors in feces: Helicobacter pylori model. J. Clin. Microbiol. 35:995-998[Abstract]. |
| 13. |
Osaki, T.,
H. Taguchi,
H. Yamaguchi, and S. Kamiya.
1998.
Detection of Helicobacter pylori in fecal samples of gnotobiotic mice infected with H. pylori by an immunomagnetic-bead separation technique.
J. Clin. Microbiol.
36:321-323 |
| 14. |
O'Toole, P. W.,
S. M. Logan,
M. Kostrzynska,
T. Wadstrom, and T. J. Trust.
1991.
Isolation and biochemical and molecular analyses of a species-specific protein antigen from the gastric pathogen Helicobacter pylori.
J. Bacteriol.
173:505-513 |
| 15. |
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 |
| 16. | Scholte, G. H. 1997. Polymerase chain reaction for the detection of Helicobacter pylori in formaldehyde-sublimate fixed, paraffin-embedded gastric biopsies. Diagn. Mol. Pathol. 6:238-243[CrossRef][Medline]. |
| 17. | Sidhu, H., M. Allison, and A. B. Peck. 1997. Identification and classification of Oxalobacter formigenes strains by using oligonucleotide probes and primers. J. Clin. Microbiol. 35:350-353[Abstract]. |
| 18. | Stacy-Phipps, S., J. J. Mecca, and J. B. Weiss. 1995. Multiplex PCR assay and simple preparation method for stool specimens detect enterotoxigenic Escherichia coli DNA during course of infection. J. Clin. Microbiol. 33:1054-1059[Abstract]. |
| 19. | Thomas, J. 1996. Culture of Helicobacter pylori from feces, p. 206-212. In A. Lee, and F. Megraud (ed.), Helicobacter pylori: techniques for clinical diagnosis and basic research. W. B. Saunders Ltd., London, England. |
| 20. | Thomas, J. E., G. R. Gibson, M. K. Darboe, A. Dale, and L. T. Weaver. 1992. Isolation of Helicobacter pylori from human faeces. Lancet 340:1194-1195[CrossRef][Medline]. |
| 21. | Tomb, J. F., O. White, A. R. Kerlavage, R. A. Clayton, G. G. Sutton, R. D. Fleischmann, K. A. Ketchum, H. P. Klenk, S. Gill, B. A. Dougherty, K. Nelson, J. Quackenbush, L. Zhou, E. F. Kirkness, S. Peterson, B. Loftus, D. Richardson, R. Dodson, H. G. Khalak, A. Glodek, K. McKenney, L. M. Fitzegerald, N. Lee, M. D. Adams, and J. C. Venter. 1997. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388:539-547[CrossRef][Medline]. (Erratum, 389:412.) |
| 22. | Trevisani, L., S. Sartori, F. Galvani, M. R. Rossi, M. Ruina, C. Chiamenti, and M. Caselli. 1999. Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces: a prospective pilot study. Am. J. Gastroenterol. 94:1830-1833[CrossRef][Medline]. |
| 23. | Vaira, D., P. Malfertheiner, F. Megraud, A. T. Axon, M. Deltenre, A. M. Hirschl, G. Gasbarrini, C. O'Morain, J. M. Garcia, M. Quina, and G. N. Tytgat. 1999. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European Study Group. Lancet 354:30-33[CrossRef][Medline]. |
| 24. |
van Zwet, A. A.,
J. C. Thijs,
A. M. Kooistra-Smid,
J. Schirm, and J. A. Snijder.
1994.
Use of PCR with feces for detection of Helicobacter pylori infections in patients.
J. Clin. Microbiol.
32:1346-1348 |
| 25. |
Weiss, J.,
J. Mecca,
E. da Silva, and D. Gassner.
1994.
Comparison of PCR and other diagnostic techniques for detection of Helicobacter pylori infection in dyspeptic patients.
J. Clin. Microbiol.
32:1663-1668 |
| 26. | Wu, L., J. Coombs, S. Malmstrom, and M. Glass. 1997. Simultaneous multianalyte nucleic acid detection for gastrointestinal bacterial pathogens using GeneSTAR technology. Clin. Lab. Med. 17:129-145[Medline]. |
| 27. | Zagari, R. M., F. Bazzoli, P. Pozzato, S. Fossi, L. De Luca, G. Nicolini, D. Berretti, and E. Roda. 1999. Non-invasive methods for the diagnosis of Helicobacter pylori infection. Ital. J. Gastroenterol. Hepatol. 31:408-415[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|